PAUL BUNN, MD
Osteopathic Medicine at 16 Ave, Denver, CO

6388054, May 14, 2002

Aug 19, 1999

09/378019

John M. Stewart - Denver CO 80210
Daniel C. F. Chan - Denver CO 80237
Lajos Gera - Denver CO 80237
Eunice York - Englewood CO 80110
Paul Bunn - Evergreen CO 80439

C07K 700

530314, 530328, 530329, 530330, 530332, 530402, 530815, 530816

The present invention provides compounds useful to inhibit tumor growth and to induce apoptosis. In general, the anti-cancer agents (ACA) are described by the formula: wherein X is a linker group having 2-5 functional groups or is absent, n=1, and ACA is selected from the group consisting of Formula II, Formula III, Formula IV, Formula V, and Formula VI, as described herein. Other compounds described herein are defined by the Formula VII, as described herein.

2010019, Aug 5, 2010

Jul 23, 2008

12/670052

Paul A. Bunn - Evergreen CO, US
Christopher D. Coldren - Denver CO, US
Wilbur A. Franklin - Denver CO, US
Mark W. Geraci - Aurora CO, US
Barbara A. Helfrich - Lakewood CO, US
Fred R. Hirsch - Denver CO, US
Razvan Lapadat - Denver CO, US
Michio Sugita - Centennial CO, US
Samir E. Witta - Greenwood Village CO, US

A61K 39/395, C12Q 1/68, A61K 31/5377, A61K 31/517, A61K 31/497

4241331, 435 6, 5142345, 5142664, 51425218, 4241411

Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.

2008022, Sep 11, 2008

May 2, 2008

12/150999

Paul Bunn - Evergreen CO, US
Samir Witta - Greenwood Village CO, US
Victoria M. Richon - Wellesley MA, US
Stanley R. Frankel - Yardley PA, US
Paul J. Deutsch - Princeton NJ, US
Sophia Randolph - Burien WA, US

A61K 31/517, A61P 35/00

5142664

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

6048550, Apr 11, 2000

Oct 2, 1997

8/942758

Daniel C. F. Chan - Denver CO
Paul Bunn - Evergreen CO
Dmitri Kirpotin - San Francisco CA

A61K 914

424497

The present invention comprises a material and a method of its preparation. The material may be described as hydrophilic microparticles, comprising a cluster of organic substance with a layer of polyelectrolyte on its surface. The present invention establishes an improved method for preparing aqueous colloidal dispersions of water-insoluble organic substances using polyionic hydrophilic polymers by which the stability of the suspension is maintained after removal of the stabilizing and/or solubilizing medium of the drug. This improved method can be utilized to formulate a variety of water-insoluble organic substances.

5411730, May 2, 1995

Jul 20, 1993

8/094790

Dmitri Kirpotin - Denver CO
Daniel C. F. Chan - Denver CO
Paul A. Bunn - Evergreen CO

Research Corporation Technologies, Inc. - Tucson AZ

A61B 5055, A61K 31715

424322

Superparamagnetic particles are provided for medical applications including hyperthermia techniques, localized heating and tissue-specific release of therapeutic agents, and magnetic resonance imaging contrast enhancement, comprising superparamagnetic iron oxide and a polymer such as dextran at a ratio of about 0. 5 to 0. 1 w/w of polymer to iron. The particles display at least one of the following magnetic properties: (a) specific power absorption rate greater than 300 w/g Fe; (b) initial magnetic susceptibility greater than 0. 7 EMU/g Fe/Gauss; and (c) magnetic moment greater than 10. sup. -15 erg/Gauss.

2007019, Aug 23, 2007

Nov 3, 2006

11/592443

Paul Bunn - Evergreen CO, US
Samir Witta - Greenwoodvillage CO, US
Victoria Richon - Wellesley MA, US
Stanley Frankel - Yardley PA, US
Paul Deutsch - Princeton NJ, US
Sophia Randolph - Burien WA, US

A61K 31/517, A61K 31/19

514266400, 514575000

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

2012014, Jun 7, 2012

Jul 23, 2008

12/670053

Samir E. Witta - Greenwood Village CO, US
Paul A. Bunn - Evergreen CO, US
Harry A. Drabkin - Denver CO, US
Robert M. Gemmill - Centennial CO, US
Daniel Chan - Denver CO, US

A61K 39/395, A61P 35/00, A61K 31/404, A61K 31/343, A61K 31/496, A61K 31/517, A61K 31/4406, A61K 38/12

4241341, 514357, 514 199, 514469, 51425218, 51426624, 514414, 4241741, 4241331, 514 194

Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.